PTAB Won't Review 2 Humira Patents In Sandoz Challenge
The Patent Trial and Appeal Board denied challenges to two patents for AbbVie Inc.'s blockbuster autoimmune drug Humira, finding that generics maker Sandoz Inc. hadn't shown they were likely invalid....To view the full article, register now.
Already a subscriber? Click here to view full article